Pharmaceuticals and Biotech Press Releases

Neil Singla, MD, CEO at Lotus Clinical Research, Speaks on Opioid Sparing Outcomes

Neil Singla, MD, CEO at Lotus Clinical Research, Speaks on Opioid Sparing Outcomes

​Lotus Clinical Research announced that Neil Singla, MD, Chief Scientific Officer spoke at Arrowhead’s Pain & Migraine Therapeutics Summit in Washington, D.C. on Sept. 23, 2019. Arrowhead’s Pain & Migraine Therapeutics Summit is the “U.S.’s premier pain conference covering the field…

NIH Grant Awarded to Akelos Collaborator, Funds Work to Develop Non-Opioid Drugs for Neuropathic Pain

NIH Grant Awarded to Akelos Collaborator, Funds Work to Develop Non-Opioid Drugs for Neuropathic Pain

A grant from the National Institutes of Health awarded to a Weill Cornell Medicine investigator will bolster Akelos Inc.-supported research to develop a non-opioid alternative to treat chronic and neuropathic pain. Akelos Inc. is in a research collaboration with Weill…

CapsCanada Expands Growth to New State-of-the-Art Facility

CapsCanada Expands Growth to New State-of-the-Art Facility

CaspCanada®, the leading innovator of vegetarian K-CAPS®, accelerates growth by relocating their headquarters to a new state-of-the-art facility strategically located in Dania Beach, Florida, with close proximity to two major interstate highways, Fort Lauderdale International Airport and Port Everglades. The new…

Lotus Clinical Research Adopts Veeva Vault CDMS to Improve Efficiency and Speed Study Timelines Across Clinical Teams

Lotus Clinical Research Adopts Veeva Vault CDMS to Improve Efficiency and Speed Study Timelines Across Clinical Teams

​​​​Lotus Clinical Research is pleased to announce that two of its Biometrics team members, Jennifer Nezzer and Andrea Krueger, presented at 2019 Veeva R&D Summit to discuss Lotus’ use of Veeva Vault CDMS, which combines EDC, coding, data cleaning, and…

TARA Biosystems Launches Cardiotype.Ca™ Cardiac Calcium Signaling Assay

TARA Biosystems, Inc. launched Cardiotype.Ca™, its in vitro system for assessing cardiac calcium signaling. The new assay can be used independently or in combination with TARA's contractility assay to evaluate the safety and efficacy of biopharmaceutical drug candidates. Calcium is…

Launch of a New Certification and Designation, Called Clinical Research Professional of Canada (CRPC)®, Offered by the Clinical Research Association of Canada (CRAC)®

Launch of a New Certification and Designation, Called Clinical Research Professional of Canada (CRPC)®, Offered by the Clinical Research Association of Canada (CRAC)®

The Clinical Research Association of Canada has launched and is now offering the only Canadian clinical research designation. The requirements and eligibility to take the exam can be found on the CRAC website. The certification exam is completely automated via the…

Language Translation a Key Component of Global Services for Clinical Trials

​Clinical trials recruit patients from all over the world. Particularly in the research of rare diseases, it is not uncommon for trial participants to travel from all corners of the globe in search of answers to their medical conditions. While…

Tecella Releases the PocketPatch, a 16-Channel USB-Powered Patch Clamp Amplifier

Tecella Releases the PocketPatch, a 16-Channel USB-Powered Patch Clamp Amplifier

Tecella proudly announces the release of the PocketPatch, its newest multi-channel patch clamp amplifier optimized for recording from ion channels embedded in planar lipid bilayers. The PocketPatch is a USB powered, small footprint device with an integrated digitizer and 16 built-in…

Orion Biotechnology to Initiate Clinical Trials of Its Innovative Microbicide Gel for HIV Prevention

Orion Biotechnology to Initiate Clinical Trials of Its Innovative Microbicide Gel for HIV Prevention

​​​​Orion Biotechnology Canada Ltd. today announced that the Polish National Regulatory Agency and Local Ethics Committee have given approval for the OB-002H-101 Phase 1 safety and acceptability study of OB-002H gel to start screening and enrollment. The OB-002H gel is…

ENT-01, Currently in Human Trials, Rejuvenates Aging Nervous System

ENT-01, Currently in Human Trials, Rejuvenates Aging Nervous System

​Enterin Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia and developing novel compounds to treat neurodegenerative diseases, announces the publication of an article entitled “Colonic motility and jejunal vagal afferent firing rates are decreased in aged adult male mice and…

RHYTHM AI Successfully Closes Seed Financing Round

RHYTHM AI Successfully Closes Seed Financing Round

RHYTHM AI Ltd ("RHYTHM AI" or "the company), a UK company focused on the treatment of Atrial Fibrillation (AF), today announces closure of a £2.15m seed financing round. AF is the most common type of abnormal heart rhythm seen in…

Recardio's Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Now Enrolling and Recruiting in All Global Centers

The clinical study is intended to evaluate the safety and efficacy of Recardio’s lead candidate dutogliptin to restore lost myocardial function in patients who experience STEMI, a severe form of heart attack, and receive percutaneous coronary intervention with stent placement.…

Emerald Lake Safety Researcher Co-Chairing Obesity Symposium at 2019 ACCP Meetings

Emerald Lake Safety Researcher Co-Chairing Obesity Symposium at 2019 ACCP Meetings

Emerald Lake Safety’s (“ELS”) Dr. Christina Chow will be co-chairing a symposium on drug safety research in obese patients on Sept. 15 at the 2019 American College of Clinical Pharmacology (ACCP) meetings in Chicago, Illinois. The symposium is a tribute…

True Diagnostics™ and Veravas, Inc. Announce Strategic Alliance in the Commercialization of VeraTest Biotin™

True Diagnostics™ and Veravas, Inc. Announce Strategic Alliance in the Commercialization of VeraTest Biotin™

​​​​True Diagnostics, Inc. (True), a leading company for Point of Care (POC) answers, and Veravas, an emerging diagnostic company focusing on proprietary sample preparation products and new diagnostic tests, announced today their Strategic Alliance in the commercialization of VeraTest Biotin, a…

V Care Biotech Offering the Best PCD Pharma Franchisee Programmes Pan India

V Care Biotech Offering the Best PCD Pharma Franchisee Programmes Pan India

Since the year 2014, V Care Biotech has made consistent headways into the Indian pharma segment with a business model based on safety, quality and innovation. Headquartered in Bangalore, the pharma company develops, manufactures and packages drugs in GMP certified…

Zensun Announces the Investigation of Neucardin for Chronic Heart Failure Receives Fast Track Designation From the US FDA

​​​​​​Zensun USA, Inc., a wholly-owned subsidiary of Zensun Sci & Tech Co. Ltd., Shanghai, announced that the investigation of NEUCARDIN®, its Recombinant human neuregulin-1 fragment, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the…

Pyxa Solutions Boosts Industry Engagement

​​​​​Pyxa Solutions, a leading provider of superior, scalable and adaptable solutions for the management of R&D submissions, information, systems and operations, today announced the appointment of Toni Lakin-Ritter as vice president of account management. Ms. Lakin-Ritter joins the team as…

Enterin's RASMET Study Published

Enterin's RASMET Study Published

​​​Enterin Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia developing novel compounds to treat neurodegenerative diseases, announces the publication of its Phase 2a RASMET study. The article entitled “Targeting neurons in the gastrointestinal tract to treat Parkinson’s Disease” was…

PharmaCord Appoints Jun Liu to Chief Technology Officer

​PharmaCord, LLC, a rapidly growing provider of patient services to life sciences companies, announced today that Jun Liu has been promoted to Chief Technology Officer. In his new role, Liu will be responsible for the architecture behind the company’s commercial technology…

Coordination Pharmaceuticals Announces Enrollment of the First Patient in Phase 1 Study of CPI-200 in Patients With Advanced Tumors

​​Coordination Pharmaceuticals Inc. (CPI), a privately-held oncology drug development company today announced that the first patient has been dosed in a Phase 1 study of CPI-200 in patients with advanced tumors. CPI-200 is a novel nanoscale coordination polymer (NCP) containing…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login